MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, announced that its burn debridement therapy NexoBrid® will be featured in 36 scientific presentations at the 21st European Burns Association Congress in Berlin (September 3-6, 2025).
The presentations will showcase data demonstrating NexoBrid's benefits in various patient populations, including pediatric, elderly, and critically burned patients. Key findings highlight improvements in survival, recovery, and scar outcomes, along with advantages in infection control and inflammatory response modulation. Studies also demonstrate NexoBrid's superiority over surgical excision in both routine care and mass casualty scenarios.
MediWound (Nasdaq: MDWD), azienda di riferimento nelle terapie enzimatiche per la riparazione dei tessuti, ha annunciato che la sua terapia per la detersione delle ustioni NexoBrid® sarà protagonista di 36 presentazioni scientifiche al 21° Congresso della European Burns Association a Berlino (3-6 settembre 2025).
Le presentazioni presenteranno dati che evidenziano i benefici di NexoBrid in diverse categorie di pazienti, tra cui pediatrici, anziani e soggetti con ustioni critiche. I risultati principali mostrano miglioramenti nella sopravvivenza, nella guarigione e negli esiti cicatriziali, oltre a vantaggi nel controllo delle infezioni e nella modulazione della risposta infiammatoria. Gli studi dimostrano anche la superiorità di NexoBrid rispetto all’escissione chirurgica sia nella pratica clinica abituale sia negli scenari di grandi emergenze.
MediWound (Nasdaq: MDWD), líder en terapias enzimáticas para la reparación de tejidos, anunció que su tratamiento de desbridamiento para quemaduras NexoBrid® será presentado en 36 comunicaciones científicas en el 21.º Congreso de la European Burns Association en Berlín (3-6 de septiembre de 2025).
Las ponencias mostrarán datos que demuestran los beneficios de NexoBrid en distintas poblaciones de pacientes, incluidos niños, ancianos y pacientes con quemaduras críticas. Los hallazgos clave resaltan mejoras en la supervivencia, la recuperación y los resultados de cicatrización, además de ventajas en el control de infecciones y la modulación de la respuesta inflamatoria. Los estudios también evidencian la superioridad de NexoBrid frente a la escisión quirúrgica tanto en la atención rutinaria como en escenarios de víctimas masivas.
MediWound (Nasdaq: MDWD), 조직 재생을 위한 효소 치료 분야의 선도 기업은 화상 제거 치료제 NexoBrid®가 2025년 9월 3일부터 6일까지 베를린에서 열리는 제21회 유럽 화상학회(European Burns Association) 학술대회에서 36건의 과학 발표로 소개될 예정이라고 발표했습니다.
발표들에서는 소아, 노인, 중증 화상 환자 등 다양한 환자군에서 NexoBrid의 효과를 입증하는 데이터를 선보입니다. 주요 결과로는 생존율, 회복 및 흉터 결과의 개선과 감염 통제 및 염증 반응 조절의 이점이 강조됩니다. 또한 일상 진료와 다수 사상자 발생 시나리오 모두에서 외과적 절제보다 NexoBrid가 우수하다는 연구 결과도 제시됩니다.
MediWound (Nasdaq: MDWD), leader des thérapies enzymatiques pour la réparation tissulaire, a annoncé que son traitement de débridement des brûlures NexoBrid® fera l’objet de 36 présentations scientifiques lors du 21e Congrès de l’European Burns Association à Berlin (3-6 septembre 2025).
Les communications mettront en avant des données montrant les bénéfices de NexoBrid chez diverses populations de patients, notamment pédiatriques, âgées et gravement brûlées. Les principales conclusions soulignent des améliorations de la survie, de la récupération et des résultats cicatriciels, ainsi que des avantages en matière de contrôle des infections et de modulation de la réponse inflammatoire. Des études démontrent également la supériorité de NexoBrid par rapport à l’excision chirurgicale, tant en soins courants que dans les scénarios de victimes en masse.
MediWound (Nasdaq: MDWD), ein führendes Unternehmen für enzymatische Therapien zur Gewebereparatur, gab bekannt, dass seine Verbrennungsdébridement-Therapie NexoBrid® auf dem 21. Kongress der European Burns Association in Berlin (3.–6. September 2025) in 36 wissenschaftlichen Beiträgen vorgestellt wird.
Die Präsentationen werden Daten zeigen, die die Vorteile von NexoBrid in verschiedenen Patientengruppen belegen, darunter pädiatrische, ältere und kritisch verbrannte Patienten. Zentrale Erkenntnisse heben Verbesserungen bei Überleben, Genesung und Narbenbildung hervor sowie Vorteile bei Infektionskontrolle und der Modulation der Entzündungsreaktion. Studien zeigen zudem die Überlegenheit von NexoBrid gegenüber chirurgischer Exzision sowohl in der Routinemedizin als auch bei Massenunfall-Szenarien.
- None.
- None.
MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin, Germany. NexoBrid®, the company’s enzymatic burn debridement therapy, will be featured in 36 scientific oral and poster presentations delivered by leading burn specialists from across Europe, highlighting its role in advancing burn care.
The presentations include data on pediatric, elderly, and critically burned patients demonstrating consistent benefits in survival, recovery, and scar outcomes, as well as value in infection control and modulation of systemic inflammatory responses. Comparative and long-term studies further support NexoBrid’s superiority over surgical excision, reaffirming its role in both routine care and mass casualty scenarios.
“NexoBrid will be prominently highlighted throughout this year’s EBA Congress, reflecting the extensive clinical data and growing real-world experience across Europe,” said Alicia Torrenova, Vice President of European Operations at MediWound. “We are encouraged to see leading burn specialists share their findings, further establishing NexoBrid as an important therapy in advancing burn care.”
About the European Burns Association
The European Burns Association (EBA), founded in 1981, brings together burn care professionals from across Europe to advance standards of treatment, research, and prevention. As a multidisciplinary forum, the EBA promotes collaboration among physicians, researchers, allied health professionals, and organizations dedicated to improving outcomes for burn patients. Through its biennial congress and ongoing initiatives, the EBA fosters the exchange of knowledge and best practices to benefit the global burn care community.
About NexoBrid®
NexoBrid® is a topically administered, biological orphan drug for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. It selectively removes non-viable tissue while preserving viable tissue and is approved for use in adults and pediatric patients in over 40 countries, including the United States, European Union, and Japan.
NexoBrid development has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C. This contract provided funding and technical support for the pivotal U.S. Phase 3 clinical study (DETECT), the randomized, controlled pivotal clinical trial for use in the pediatric population (CIDS), the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access treatment protocol (NEXT). Additional projects for evaluation of NexoBrid funded under the BARDA contract include establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market adoption in the United States.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information visit www.mediwound.com and follow us on LinkedIn.
MediWound Contacts: Media Contact:
Hani Luxenburg Daniel Ferry Ellie Hanson
Chief Financial Officer Managing Director Partner
MediWound Ltd. LifeSci Advisors, LLC FINN Partners for MediWound
ir@mediwound.com daniel@lifesciadvisors.com ellie.hanson@finnpartners.com
FAQ
What is the significance of NexoBrid's 36 presentations at the 2025 EBA Congress?
When and where is MediWound (MDWD) presenting at the European Burns Association Congress 2025?
What patient populations will be covered in NexoBrid's clinical data presentations?
How does NexoBrid compare to surgical excision according to the presented studies?
What are the key benefits of MediWound's NexoBrid treatment highlighted in the presentations?
